China-based Contract Development and Manufacturing Organization (CDMO) Suzhou Porton Biologics Ltd has entered into a strategic partnership with compatriot firm BRL Medicine Inc. The collaboration aims to deepen their involvement in the gene and cell therapy (GCT) pipeline, enhance clinical studies, and expedite the commercialization of novel therapies.
BRL Medicine’s GCT Product Portfolio and IND Filings
BRL Medicine is advancing multiple GCT products at the IND filing stages, with three core products having received IND approvals in China. These include the hematopoietic stem cell platform (ModiHSC)-based gene therapy BRL-101 and the non-virus targeted integration CAR-T platform-based CAR-T therapy BRL-201. These therapies represent significant advancements in the field of GCT and highlight BRL Medicine’s commitment to innovative treatment solutions.
Porton Bio’s Comprehensive CDMO Services for GCT
Porton Bio, on the other hand, prides itself on offering an end-to-end CDMO service platform for gene and cell therapy. This comprehensive platform covers a wide range of therapeutic areas, including plasmids, cell therapy, gene therapy, oncolytic viruses, nucleic acid therapy, and live bacterial therapy. Porton Bio’s expertise and capabilities are set to play a crucial role in supporting the development and manufacturing of GCT products, from preclinical stages to commercialization.-Fineline Info & Tech
